Project Description: Business Feasibility Assessment for Molecules Targeting Mitochondrial Diseases
The Triana Group is seeking a consultant with the expertise and relationships necessary to perform a preliminary business feasibility assessment as described below. Proposals are due Dec 28. Selection announced Jan 14. Project start date: Feb 4, 2016. Deliverable due: April 2016.
About the molecules
- Patent filed
- Preliminary assessment
- Invention: new therapeutic application of 2 FDA approved medicines and 1 in clinical studies in the USA.
- Diseases targeted: 1 in 4,500 newborn, currently with no treatment available.
- 3 molecules selected as extremely promising following screening and testing on human cells.
- Applicable to 27 mitochondrial diseases.
Expected Deliverable
Activities
- Interviews to further assess interest level towards the innovation (once retained, the consultant will submit to client their identity for approval, to check conflict of interests)
- Detect new partners
Questions to be answered
- What are the options to take this innovation to market
- What is the best strategy
- What constraints and standards need to be taken into account for market access
- Who are the key players on this market
- Advice on the innovation’s market potential (provide advice on option to create a start-up vs. to license out; go/ no-go; recommendation on how to best build value with the innovation in the mid-term (2016-2020) from the following perspectives: technical; financial; legal)
- Which industrial partners most likely to be interested, which contacts within the companies
Report’s content
- Responses to questions listed above
- Detailed interview notes (including interview guide and complete notes)
- Names and details of people interviewed
- Other sources used
To express interest: contact us